Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

viking therapeutics inc. - VKTX

VKTX

Close Chg Chg %
25.66 0.34 1.33%

Closed Market

26.00

+0.34 (1.33%)

Volume: 10.59M

Last Updated:

Aug 22, 2025, 4:00 PM EDT

Trade Now

Company Overview: viking therapeutics inc. - VKTX

VKTX Key Data

Open

$25.38

 Day Range

24.96 - 26.65

52 Week Range

18.92 - 81.73

 Market Cap

$2.89B

Shares Outstanding

112.45M

 Public Float

109.09M

Beta

0.67

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$1.53

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

8.67M

  

VKTX Performance

1 Week
 
 -35.05%
 
1 Month
 
 -24.46%
 
3 Months
 
 -3.63%
 
1 Year
 
 -59.77%
 
5 Years
 
 227.87%
 

VKTX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 17
Full Ratings ➔
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Viking Therapeutics Inc. - VKTX

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
296.00K 291.00K 292.00K 346.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
296.00K 291.00K 292.00K 346.00K
Depreciation
296.00K 291.00K 292.00K 346.00K
Amortization of Intangibles
- - - -
-
COGS Growth
+6.86% -1.69% +0.34% +18.49%
Gross Income
(296.00K) (291.00K) (292.00K) (346.00K)
Gross Income Growth
-6.86% +1.69% -0.34% -18.49%
Gross Profit Margin
- - - -
-
2021 2022 2023 2024 5-year trend
SG&A Expense
55.39M 70.06M 100.53M 150.57M
Research & Development
44.98M 54.23M 63.81M 101.64M
Other SG&A
10.40M 15.83M 36.73M 48.93M
SGA Growth
+30.67% +26.50% +43.49% +49.77%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(55.68M) (70.36M) (100.83M) (150.92M)
Non Operating Income/Expense
710.00K 1.55M 15.02M 41.05M
Non-Operating Interest Income
703.00K 1.59M 15.02M 40.94M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
18.00K 59.00K 88.00K 94.00K
Interest Expense Growth
-83.02% +227.78% +49.15% +6.82%
Gross Interest Expense
18.00K 59.00K 88.00K 94.00K
Interest Capitalized
- - - -
-
Pretax Income
(54.99M) (68.87M) (85.89M) (109.96M)
Pretax Income Growth
-39.23% -25.24% -24.73% -28.02%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(54.99M) (68.87M) (85.89M) (109.96M)
Minority Interest Expense
- - - -
-
Net Income
(54.99M) (68.87M) (85.89M) (109.96M)
Net Income Growth
-39.23% -25.24% -24.73% -28.02%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(54.99M) (68.87M) (85.89M) (109.96M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(54.99M) (68.87M) (85.89M) (109.96M)
EPS (Basic)
-0.7123 -0.8963 -0.9104 -1.0085
EPS (Basic) Growth
-30.94% -25.83% -1.57% -10.78%
Basic Shares Outstanding
77.20M 76.83M 94.35M 109.04M
EPS (Diluted)
-0.7123 -0.8963 -0.9104 -1.0085
EPS (Diluted) Growth
-30.94% -25.83% -1.57% -10.78%
Diluted Shares Outstanding
77.20M 76.83M 94.35M 109.04M
EBITDA
(55.39M) (70.06M) (100.53M) (150.57M)
EBITDA Growth
-30.67% -26.50% -43.49% -49.77%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 90.438
Number of Ratings 17 Current Quarters Estimate -0.674
FY Report Date 09 / 2025 Current Year's Estimate -2.471
Last Quarter’s Earnings -0.58 Median PE on CY Estimate N/A
Year Ago Earnings -1.01 Next Fiscal Year Estimate -3.099
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 17 17 14 16
Mean Estimate -0.67 -0.72 -2.47 -3.10
High Estimates -0.32 -0.32 -2.23 -2.23
Low Estimate -0.82 -0.97 -2.77 -4.35
Coefficient of Variance -18.30 -19.86 -7.12 -18.81

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 15 17 17
OVERWEIGHT 0 0 0
HOLD 2 2 2
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Viking Therapeutics Inc. - VKTX

Date Name Shares Transaction Value
Apr 15, 2025 Matthew William Foehr Director 132,036 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $8 per share 1,056,288.00
Apr 15, 2025 Matthew William Foehr Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 9, 2025 S. Kathryn Rouan Director 1,240 Open market or private purchase of non-derivative security Non-derivative transaction at $24.15 per share 29,946.00
Aug 23, 2024 J. Matthew Singleton Director 15,200 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.19 per share 18,088.00
Aug 23, 2024 J. Matthew Singleton Director 9,500 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $69.72 per share 662,340.00
Aug 23, 2024 J. Matthew Singleton Director 10,300 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 23, 2024 Brian Lian President & CEO; Director 2,355,927 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $7.77 per share 18,305,552.79
Aug 23, 2024 Brian Lian President & CEO; Director 2,354,927 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $69.9 per share 164,609,397.30
Aug 23, 2024 Brian Lian President & CEO; Director 231,130 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Viking Therapeutics Inc. in the News